Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Cell-Free DNA Genomic and Fragmentomic Features for Early Outcome Prediction in Diffuse Large B-Cell Lymphoma

Blood (2024) 144 (Supplement 1): 1588.

https://doi.org/10.1182/blood-2024-206636

Published: 2024

Journal Articles

Immunosuppressed Tumor Microenvironment in MYC -Rearranged High-Grade B-Cell Lymphomas Compared to Diffuse Large B-Cell Lymphomas, Not Otherwise Specified

Blood (2024) 144 (Supplement 1): 4380.

https://doi.org/10.1182/blood-2024-205968

Published: 2024

Journal Articles

No Discernable Dysfunction of Peripheral T-Cells and NK-Cells Despite Distinct Phenotypes in MYC Rearranged Versus Non Rearranged B-Cell Lymphoma Patients

A. Vera de Jonge, Carolien Duetz, Wassilis S.C Bruins, Charlotte L.B.M. Korst, Rosa Rentenaar, Meliha Cosovic, Merve Eken, Inoka Twickler, Marcel Nijland, Marjolein Van Der Poel, Koen de Heer, Clara Klerk, Leonie Strobbe, Margriet Oosterveld, Rinske Boersma, Harry R. Koene, Erik van Werkhoven, Martine E.D. Chamuleau, Tuna Mutis

Blood (2023) 142 (Supplement 1): 1653.

https://doi.org/10.1182/blood-2023-180734

Published: 2023

Journal Articles

Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL

Blood (2023) 142 (13): 1131–1142.

https://doi.org/10.1182/blood.2023020195

Published: 2023

Includes: Supplemental data

Journal Articles

A Propensity Score-Adjusted Comparison of Lenalidomide + R-CHOP Versus R-CHOP for MYC -Rearranged DLBCL Patients

A. Vera de Jonge, Erik D. van Werkhoven, Avinash G. Dinmohamed, Marcel Nijland, Aeilko H. Zwinderman, Patrick M. Bossuyt, Martine S. Veldhuis, Emma G.G.M. Rutten, Rogier Mous, Joost S.P. Vermaat, Yorick Sandberg, Eva de Jongh, Yavuz M. Bilgin, Rinske Boersma, Harry R. Koene, Marie Jose Kersten, Daphne de Jong, Martine E.D. Chamuleau

Blood (2022) 140 (Supplement 1): 2059–2060.

https://doi.org/10.1182/blood-2022-163204

Published: 2022

Journal Articles

A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial

Blood (2021) 138 (Supplement 1): 71.

https://doi.org/10.1182/blood-2021-146161

Published: 2021

Journal Articles

HOVON 104; Results of First 25 Patients from a Multicenter, Multinational, Prospective Phase II Study of Bortezomib Based Induction Treatment Followed By Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Al Amyloidosis

Monique Minnema, Kazem Nasserinejad, MA, Bouke Hazenberg, MD PhD, Ute Hegenbart, Lucien Noens, MD PhD, Paula F. Ypma, MD, Sonja Zweegman, MD PhD, Lidwine Winnifred Tick, MD PhD, Annemiek Broijl, MD PhD, Harry R. Koene, MD PhD, Gerard M.J. Bos, MD PhD, Pieter Sonneveld, MD PhD, Stefan O. Schoenland, MD

Blood (2016) 128 (22): 4628.

https://doi.org/10.1182/blood.V128.22.4628.4628

Published: 2016

Journal Articles

Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma

Blood (2016) 128 (19): 2297–2306.

https://doi.org/10.1182/blood-2016-07-729236

Published: 2016

Includes: Supplemental data

Journal Articles

Phase 1/2 Trial Of Lenalidomide In Combination With Cyclophosphamide and Prednisone (REP) In Patients With Lenalidomide-Refractory Multiple Myeloma (REPEAT-study)

Inger S. Nijhof, MD, Sonja Zweegman, MD PhD, Mark-David Levin, MD PhD, Harry R. Koene, MD PhD, Aart Beeker, MD, Andries C. Bloem, PhD, Gerard M.J. Bos, MD PhD, Laura M. Faber, MD PhD, Saskia K. Klein, MD PhD, Evert-Jan F.M. de Kruijf, MD, Ellen van der Spek, MD PhD, Shulamiet Wittebol, MD PhD, Jeroen F. van Velzen, Berris van Kessel, Tuna Mutis, MD, PhD, Pieter Sonneveld, MD, Ph.D, Henk Lokhorst, Niels W.C.J. van de Donk, MD, PhD

Blood (2013) 122 (21): 287.

https://doi.org/10.1182/blood.V122.21.287.287

Published: 2013

Journal Articles

Interim Analysis on a Dutch HOVON Multicenter Randomized Open Label Phase II Trial on 3 Rituximab Dosing Schemes In Chronic ITP Patients:

Jaap Jan Zwaginga, MD, PhD, Ronnie van der Holt, PhD, Bart J. Biemond, MD, PhD, Peter A.W. te Boekhorst, MD, PhD, Mark Levin, MD, PhD, Art Vreughdenhil, MD, PhD, P.C. Huijgens, MD, PhD, Anneke Brand, MD, PhD, Rene van der Griend, MD, PhD, Marleen Luten, Hans Pruijt, MD, PhD, Okke de Weerdt, Elisabeth van Pampus, MD, PhD, Sonja Zweegman, MD, PhD, Rene Hollestein, Harry R. Koene, MD, PhD

Blood (2010) 116 (21): 2514.

https://doi.org/10.1182/blood.V116.21.2514.2514

Published: 2010

Journal Articles

Platelets Contribute to Protein S Cleavage In Vivo.

Herm Jan M Brinkman, Liane CJ te Boome, Harry R Koene, Koen Mertens

Blood (2009) 114 (22): 2124.

https://doi.org/10.1182/blood.V114.22.2124.2124

Published: 2009

Journal Articles

Copy number variation of the activating FCGR2C gene predisposes to idiopathic thrombocytopenic purpura

Willemijn B. Breunis, Edwin van Mirre, Marrie Bruin, Judy Geissler, Martin de Boer, Marjolein Peters, Dirk Roos, Masja de Haas, Harry R. Koene, Taco W. Kuijpers

Blood (2008) 111 (3): 1029–1038.

https://doi.org/10.1182/blood-2007-03-079913

Published: 2008

Includes: Supplemental data

Journal Articles

Clinical Value of Soluble IgG Fc Receptor Type III in Plasma From Patients With Chronic Idiopathic Neutropenia

Harry R. Koene, Masja de Haas, Marion Kleijer, Tom W.J. Huizinga, Dirk Roos, Albert E.G.Kr. von dem Borne

Blood (1998) 91 (10): 3962–3966.

https://doi.org/10.1182/blood.V91.10.3962

Published: 1998

Journal Articles

FcγRIIIB Gene Duplication: Evidence for Presence and Expression of Three Distinct FcγRIIIB Genes in NA(1+,2+)SH(+) Individuals

Harry R. Koene, Marion Kleijer, Dirk Roos, Masja de Haas, Albert E.G.Kr. Von dem Borne

Blood (1998) 91 (2): 673–679.

https://doi.org/10.1182/blood.V91.2.673

Published: 1998

Journal Articles

FcγRIIIa-158V/F Polymorphism Influences the Binding of IgG by Natural Killer Cell FcγRIIIa, Independently of the FcγRIIIa-48L/R/H Phenotype

Harry R. Koene, Marion Kleijer, Johan Algra, Dirk Roos, Albert E.G.Kr. von dem Borne, Masja de Haas

Blood (1997) 90 (3): 1109–1114.

https://doi.org/10.1182/blood.V90.3.1109

Published: 1997

NARROW

Cell-Free DNA Genomic and Fragmentomic Features for Early Outcome Prediction in Diffuse Large B-Cell Lymphoma

Immunosuppressed Tumor Microenvironment in MYC -Rearranged High-Grade B-Cell Lymphomas Compared to Diffuse Large B-Cell Lymphomas, Not Otherwise Specified

No Discernable Dysfunction of Peripheral T-Cells and NK-Cells Despite Distinct Phenotypes in MYC Rearranged Versus Non Rearranged B-Cell Lymphoma Patients

Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL

A Propensity Score-Adjusted Comparison of Lenalidomide + R-CHOP Versus R-CHOP for MYC -Rearranged DLBCL Patients

A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial

HOVON 104; Results of First 25 Patients from a Multicenter, Multinational, Prospective Phase II Study of Bortezomib Based Induction Treatment Followed By Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Al Amyloidosis

Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma

Phase 1/2 Trial Of Lenalidomide In Combination With Cyclophosphamide and Prednisone (REP) In Patients With Lenalidomide-Refractory Multiple Myeloma (REPEAT-study)

Interim Analysis on a Dutch HOVON Multicenter Randomized Open Label Phase II Trial on 3 Rituximab Dosing Schemes In Chronic ITP Patients:

Platelets Contribute to Protein S Cleavage In Vivo.

Copy number variation of the activating FCGR2C gene predisposes to idiopathic thrombocytopenic purpura

Clinical Value of Soluble IgG Fc Receptor Type III in Plasma From Patients With Chronic Idiopathic Neutropenia

FcγRIIIB Gene Duplication: Evidence for Presence and Expression of Three Distinct FcγRIIIB Genes in NA(1+,2+)SH(+) Individuals

FcγRIIIa-158V/F Polymorphism Influences the Binding of IgG by Natural Killer Cell FcγRIIIa, Independently of the FcγRIIIa-48L/R/H Phenotype

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only